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The Editorial on the Research Topic
Ontogeny and Phylogeny of Brain Barrier Mechanisms
The protective barriers of the central nervous system, positioned at interfaces between the brain,
spinal cord and the periphery, are often considered as gatekeepers—restricting entry of unwanted
molecules and ensuring an effective maintenance of the delicate microenvironment of the central
nervous system. While there is truth in this depiction, it does not fully capture the highly dynamic
nature of these brain barrier systems; the specific regulation of transporters, the signaling between
endothelial cells and other components of the neurovascular unit; or the precise regulation of
cerebrospinal fluid composition via the choroid plexus, that changes appropriately both during
development and throughout aging.
In this Frontiers Topic on Ontogeny and phylogeny of brain barrier mechanisms, we celebrate
the advances made in understanding the normal structure and function of these mechanisms in
a diverse range of organisms. The study of development and non-mammalian species shows the
similarities of many brain barrier mechanisms as well some diversity.
Substantial information is now available about the protein composition of tight junctions,
an integral component of barrier structure. As well as recent investigations on interaction
of protein components, we are gaining insights into the polarity changes in endothelial
and epithelial cells required for correct establishment of tight junctions (Bauer et al.). The
polarization of cells at brain barriers is also key for regulation of transport, such has been
clearly indicated for influx (Saunders et al.) and eﬄux transporters (Strazielle and Ghersi-Egea).
The important transport role of the barrier systems in relation to brain development has been
highlighted for thyroid hormone in the review by Richardson et al. Genomic studies highlight
molecular diversity of the barriers, which show substantial changes in gene regulation with age,
species and at different barrier sites (Bill and Korzh; Bueno et al. DeSalvo et al.; Johansson;
Limmer et al.; Ek et al.; Saunders et al.; Strazielle and Ghersi-Egea). The use of non-mammalian
animal models has advanced the capacity to interrogate the molecular diversity of the barrier
systems (DeSalvo et al.; Henson et al.; Hindle and Bainton; Limmer et al.). Zebrafish in particular,
because of their transparency, provide an unparalleled opportunity to observe directly at high
resolution the development of particular aspects of barrier function (Bill and Korzh; Henson
et al.). This plethora of species represents fantastic opportunities for further investigation of how
regulation of gene or protein production affects barrier function.
The new genomic studies included in this Topic also report enrichment of genes not just for
cell adhesion and solute transport, but also metabolism and cell signaling (DeSalvo et al.; Limmer
et al.) indicate a more integrated, deterministic role of the barrier systems in brain function. This
integration is particularly evident in neurogenic niches where proliferation and differentiation of
cells are in part regulated by contact or release of signaling molecules from cells that comprise these
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barriers (Stolp and Molnár). To further emphasize this point,
Errede et al. provide an elegant study showing cross-talk between
blood vessels and radial glia within the developing human
cerebral cortex.
For research into this complex biological system to advance
further, it is necessary for a number of important concepts
to be addressed. First, there needs to be consistent and
accurate definitions of brain barrier systems. Second, recognition
is required that barrier systems in development are not
just present and functional, but also integral for facilitating
normal brain growth. And third, there is an urgent need for
identification and community-wide implementation of well-
described, reproducible and meaningful assessments of barrier
function.
Significant progress has been made regarding the first two of
these concepts. In this special Topic Whish et al. and Brøchner
et al. explore two under-studied barriers in the developing brain.
These authors elegantly demonstrate multiple components of
the barrier system at the inner and outer CSF-brain interfaces,
and how these differ from blood-brain and blood-CSF barriers.
Brøchner et al. extend on the barrier definitions outlined by
Saunders et al. (2008). In particular they identify 3 distinct
morphological components (arachnoid barrier cell layer, pial
microvessels, and glial end feet/pial surface layer) that contribute
to the outer CSF-brain barrier interface that has previously been
treated as a single entity. Bueno et al. review experiments on very
early stages of brain development shortly after neural tube closure
in the chick embryo. This is a stage that has otherwise received
very little attention. They describe a subset of endothelial cells in
the ventral mesencephalon and anterior ventral prosencephalon
with transient transport properties that they suggest parallel
the functions of the choroid plexuses before these structures
differentiate.
The misconception that brain barrier systems are immature
in the developing brain is still frequently touted in the literature,
despite evidence to the contrary dating back to experiments
conducted in the early twentieth century (see Saunders et al.).
In this special Topic, further evidence is presented on age-
and region-specific regulation of influx and eﬄux transporters
(Saunders et al.; Strazielle and Ghersi-Egea)—as described above,
the developing brain actually has more individual barrier systems
than in the adult (Bueno et al.; Brøchner et al.; Whish et al.).
The choroid plexus in particular is a complex set of barrier
mechanisms that are present from an extremely early stage
of brain development (Liddelow). The evidence presented on
progenitor cells specifically sitting in CSF and vascular niches
points to a tightly controlled environment with specific signaling
mechanisms appropriate for different stages of the development
of the brain is particularly striking. This contradicts the long
held immature brain barrier hypothesis (Bueno et al.; Johansson;
Stolp and Molnár). There is also evidence for an additional
neurogenic niche in the choroid plexus stroma (Prasongchean
et al.), which these authors suggest contributes specifically to
prenatal innervation of the choroid plexus and regulation of CSF
secretion.
While there are huge advances in our understanding of
structural (e.g., tight junction) proteins and transporter systems
at brain barriers during development and aging in a wide variety
of species, we are still limited in our understanding of how these
elements of the barrier systems are altered following injury or
during disease. The field is currently most interested in barrier
dysfunction in the adult and aging brain, aspects that are outside
the scope of this Topic. However, barrier dysfunction during
development has implications not only for the fetus or newborn
acutely at the time of the disorder but also chronically with
the possibility of long-term consequences. Here Moretti et al.
provide an overview of disorders that involve brain barrier
mechanisms including their long-term sequelae. Kratzer et al.
deal with the specific developmental problem of neonatal stroke;
while Palmela et al. provide some in vitro data on the problem
of neonatal kernicterus. The role of the blood-brain barrier in
neonatal bilirubin encephalopathy is much more complex than
the longstanding simple view that it occurs because of barrier
absence or immaturity (see Saunders et al.).
Both in the developmental and adult brain barrier fields we
are missing a consensus on the appropriate methodologies that
should be used to understand barrier function. For example,
quantification of tight junction proteins is a common assessment
in injury models to determine whether structural elements of
barriers are functioning effectively. However, there is no clear
indication of (a) what effect reduction in tight junction proteins
produces, or (b) how changes in expression of tight junction
protein genes or cellular content of these proteins relate to
structural integrity of junctions. To make claims about loss of
barrier integrity requires ultrastructural studies with suitable
markers that are visible at high resolution, something that is
rarely done. If brain barrier studies are to integrate with a
proper understanding of neurological injury we need substantial
improvement in our assessments of barrier function. This focus
on structural proteins of brain barriers also means that active
transport systems, important for understanding of energetics
of the barriers, are rarely studied. This is despite evidence of
high metabolic function of cerebral endothelial cells compared
to those in the periphery (Oldendorf et al., 1977). While tracer
studies still represent a functional measure, irrespective of
mechanism, there are substantial problems with how these have
been administered and interpreted (see Saunders et al.).
Leukocyte infiltration into the brain during injury is often
used as an indication of barrier dysfunction, but is a finding
that is not interpreted so easily. Leukocytes cross into the
brain under control conditions as part of the normal immune
surveillance of the brain (Ransohoff and Engelhardt, 2012), but
it is unclear whether the massive influx of leukocytes into the
brain (e.g., in Multiple Sclerosis active lesions) is a dysfunction
of the barrier, or a normal pathological response resulting
from abnormal signaling in the brain. There is evidence from
perinatal brain injury of leukocyte populations entering the
brain and contributing to injury at a time when the adaptive
immune system had previously been considered immature and
unresponsive (Wang and Mallard, 2016). It is unclear whether
some of these cells are also contributing to resolution of the
lesion, or whether they only produce negative effects on the brain.
Whatever the reason for peripheral immune cell infiltration,
there is increasing evidence of beneficial effects of controlled
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neuroinflammation in pathological conditions (Mardiguian et al.,
2013; Evans et al., 2014; Amantea and Bagetta, 2016).
Clear guidelines for conducting genomic or proteomic studies
of barrier systems are now provided (Huntley et al.; Torbett
et al.). What remains is for these studies to extend from an
analysis of normal barrier interfaces, to studies of heterogeneity
of barrier systems and of cerebral endothelial cells (Macdonald
et al., 2010) as well as responses to injury and other pathological
conditions. Similarly, there is need for a battery of standardized
tests for barrier function, including tracers and other measures of
barrier integrity as well as transporter presence and function. For
a full understanding of normal and abnormal barrier function
these should be performed together, in whole systems studies at
macro- and microscopic levels. The wide range of molecular and
physiological tools available, as well as the multiple in vitro and
in vivomodels, means that these aims are well within reach.
Two problems that have been a major preoccupation in
the blood-brain barrier field over recent decades have been
how to screen drugs with potential therapeutic value for
treating neurological disorders, and how to devise methods
for effective delivery of such drugs to the brain. In spite of
a considerable expenditure of time and resources outcomes
have been disappointing, perhaps in part because of an undue
focus on in vitro methods. Although not a specific focus of
this Topic, several of the papers point to contributions that
are, or could be made by approaches described here. Thus,
Hindle and Bainton describe promising live imaging approaches
in Drosophila, supported by the report of DeSalvo et al. that
the transcriptomes of fly and mouse show many similarities
particularly with respect to the ABC eﬄux transporters that
prevent the entry of so many drugs into the central nervous
system. The advances in understanding of many different aspects
of barrier function described in the papers in this Topic hold
promise for developing better drug delivery systems both in vivo
and in improved in vitro systems.
The twenty-five reviews and original research articles in this
Topic, provide a comprehensive update on the state of these
research fields, their interrelations and implications for the
blood-brain barrier field as a whole. We should like to thank all
the authors and additional editors for their splendid and patient
contributions to the Topic. We hope that the Topic articles
will provide both a benchmark and reference point for future
studies.
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